CLINICAL TRIALS PROFILE FOR BACLOFEN
✉ Email this page to a colleague
All Clinical Trials for baclofen
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000303 ↗ | Rapid Evaluation of Baclofen for Treatment of Cocaine Abuse/Dependence - 6 | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 1997-10-01 | The purpose of this study is to empirically test a series of medications to: 1) determine each medication's efficacy in treatment of cocaine abuse/dependence; 2) find most effective dose range for each medication. In this study, baclofen is tested. |
| NCT00000303 ↗ | Rapid Evaluation of Baclofen for Treatment of Cocaine Abuse/Dependence - 6 | Completed | University of California, Los Angeles | Phase 2 | 1997-10-01 | The purpose of this study is to empirically test a series of medications to: 1) determine each medication's efficacy in treatment of cocaine abuse/dependence; 2) find most effective dose range for each medication. In this study, baclofen is tested. |
| NCT00004431 ↗ | Randomized Study of L-Baclofen in Patients With Refractory Trigeminal Neuralgia | Completed | University of Pittsburgh | N/A | 1998-06-01 | OBJECTIVES: I. Evaluate the efficacy of L-baclofen in patients with refractory trigeminal neuralgia. II. Evaluate the safety and tolerance of L-baclofen in these patients. |
| NCT00082485 ↗ | Baclofen for the Treatment of Cocaine Dependence - 1 | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 2004-06-01 | The purpose of this study is to assess the efficacy and safety of baclofen for the treatment of cocaine dependence. |
| NCT00139789 ↗ | A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis | Completed | UCB Pharma | Phase 3 | 2005-01-01 | This was a multicenter, open-label, randomized, crossover trial in subjects with MS who were already taking a stable dose of baclofen (up to 80 mg/day) for spasticity. The trial was designed to assess subject preference for Kemstro or conventional baclofen. At Visit 1, subjects were screened, and if qualified, were randomly assigned to one of two following treatment sequences: Kemstro/conventional baclofen or conventional baclofen/Kemstro. |
| NCT00142883 ↗ | The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3 | Terminated | National Institute on Drug Abuse (NIDA) | N/A | 2004-09-01 | Gamma-aminobutyric acid (GABA) is a type of neurotransmitter, which is a chemical that transmits information within and from the brain to all parts of the body. By lowering the level of another neurotransmitter called dopamine, GABA may have the ability to diminish cocaine cravings in addicts. The purpose of this study is to gather information on the interaction between cocaine and selected GABA enhancing medications in individuals addicted to cocaine. This may lead to future clinical studies using GABA medications to treat cocaine addiction. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for baclofen
Condition Name
Clinical Trial Locations for baclofen
Trials by Country
Clinical Trial Progress for baclofen
Clinical Trial Phase
Clinical Trial Sponsors for baclofen
Sponsor Name
